Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

J App Pharm Sci. 2017; 7(11): 119-125


ASSESSMENT OF QUALITY OF LIFE AND SEVERITY OF ITCHING PRE AND POST DOXEPIN THERAPY IN DIALYSIS PATIENTS WITH PRURITUS

Kousalya Prabahar, Danda Anusha, Soundararajan Periasamy, Boddu Sri Venkata Rishitha, Anand Ramanathan, Dasari Anudeep.




Abstract

Objective: Chronic kidney disease (CKD)-associated pruritus is a significant clinical symptom affecting more than 50% of patients on hemodialysis. The main aim of this study was to assess the effects of doxepin treatment on the quality of life of pruritic patients.
Material and methods: This prospective-interventional study was carried out for a period of 6 months in dialysis unit of Department of Nephrology in a tertiary care teaching hospital, Chennai. Both inpatients and outpatients of both sexes ≥ 18 years on hemodialysis or peritoneal dialysis for more than 3 months with pruritus were included for the study. A total number of 39 dialysis patients with pruritus were recruited for the study. Patients were evaluated at the beginning of the study and at the end of 2 weeks of each study period. The severity, duration, degree, direction, disability and distribution of itch were evaluated using 5D- pruritus scale. The quality of life of patients was assessed using DLQI questionnaire (Dermatology Life Quality Index).
Results: There was an improvement in quality of life of patients with pruritus after doxepin therapy.
Conclusion: Doxepin is a better therapy for itching and improving the quality of life in dialysis patients. Clinicians should enquire about skin irritation and itching during consultations since patients may be reluctant to admit to these symptoms due to embarrassment.

Key words: Itch; pruritus; doxepin.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.